Association Between Utilization of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter-2 Inhibitors and Cardiovascular Events in Medicare Beneficiaries with Type 2 Diabetes

Cardiovascular disease remains a major health concern for people living with type 2 diabetes, even as treatment options continue to expand. As utilization of GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose contransporter-2 inhibitors (SGLT2i) grows among Medicare beneficiaries, understanding which patient and clinical factors are associated with cardiovascular events becomes increasingly important. Real-world evidence may provide insight into opportunities for earlier risk identification and more targeted interventions for individuals at increased cardiovascular risk.